| PERUSINI, MA., TS. KIM, Daniela ŽÁČKOVÁ, K. PAGNANO, Jiří MAYER, C. PAVLOVSKY, Ivana JEŽÍŠKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, B MOIRAGHI, AI. VARELA, M. BIANCHINI, ABP. LOPES, G. DUARTE, YS. YOO, CA. SOUZA, J. MEDEIROS, HW. LEE, KH. KIM, SY. YI, MH. CHANG, S. ABELSON a DDH. KIM. The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy. In 64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood. 2022. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2241067,
author = {Perusini, MA. and Kim, TS. and Žáčková, Daniela and Pagnano, K. and Mayer, Jiří and Pavlovsky, C. and Ježíšková, Ivana and Kvetková, Anežka and Jurček, Tomáš and Moiraghi, B and Varela, AI. and Bianchini, M. and Lopes, ABP. and Duarte, G. and Yoo, YS. and Souza, CA. and Medeiros, J. and Lee, HW. and Kim, KH. and Yi, SY. and Chang, MH. and Abelson, S. and Kim, DDH.},
booktitle = {64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood},
title = {The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy},
year = {2022}
}
TY - CONF
ID - 2241067
AU - Perusini, MA. - Kim, TS. - Žáčková, Daniela - Pagnano, K. - Mayer, Jiří - Pavlovsky, C. - Ježíšková, Ivana - Kvetková, Anežka - Jurček, Tomáš - Moiraghi, B - Varela, AI. - Bianchini, M. - Lopes, ABP. - Duarte, G. - Yoo, YS. - Souza, CA. - Medeiros, J. - Lee, HW. - Kim, KH. - Yi, SY. - Chang, MH. - Abelson, S. - Kim, DDH.
PY - 2022
TI - The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
ER -
PERUSINI, MA., TS. KIM, Daniela ŽÁČKOVÁ, K. PAGNANO, Jiří MAYER, C. PAVLOVSKY, Ivana JEŽÍŠKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, B MOIRAGHI, AI. VARELA, M. BIANCHINI, ABP. LOPES, G. DUARTE, YS. YOO, CA. SOUZA, J. MEDEIROS, HW. LEE, KH. KIM, SY. YI, MH. CHANG, S. ABELSON a DDH. KIM. The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy. In \textit{64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood}. 2022.
|
